Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
Total Valuation
Neumora Therapeutics, Inc. has a market cap or net worth of $122.52M. The enterprise value is $1.40B.
Market Cap$122.52M
Enterprise Value$1.40B
Share Statistics
Neumora Therapeutics, Inc. has 161,747,920 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding161,747,920
Owned by Insiders25.49%
Owned by Institutions0.12%
Financial Efficiency
Neumora Therapeutics, Inc.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee0.00
Profits Per Employee-2.22M
Employee Count110
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Neumora Therapeutics, Inc. is -6.93. Neumora Therapeutics, Inc.’s PEG ratio is -2.58.
PE Ratio-6.93
PS Ratio―
PB Ratio5.89
Price to Fair Value5.89
Price to FCF-9.23
Price to Operating Cash Flow-9.23
PEG Ratio-2.58
Income Statement
In the last 12 months, Neumora Therapeutics, Inc. had revenue of 0.00 and earned -243.79M in profits. Earnings per share was -1.53.
Revenue0.00
Gross Profit0.00
Operating Income-263.46M
Pretax Income-243.61M
Net Income-243.79M
EBITDA-263.46M
Earnings Per Share (EPS)-1.53
Cash Flow
In the last 12 months, operating cash flow was -182.94M and capital expenditures 0.00, giving a free cash flow of -182.94M billion.
Operating Cash Flow-182.94M
Free Cash Flow-182.94M
Free Cash Flow per Share-1.13
Dividends & Yields
Neumora Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.11
52-Week Price Change-91.97%
50-Day Moving Average1.18
200-Day Moving Average7.89
Relative Strength Index (RSI)34.84
Average Volume (3m)1.18M
Important Dates
Neumora Therapeutics, Inc. upcoming earnings date is May 13, 2025, TBA Not Confirmed.
Last Earnings DateMar 3, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Neumora Therapeutics, Inc. as a current ratio of 10.51, with Debt / Equity ratio of 0.65%
Current Ratio10.51
Quick Ratio10.51
Debt to Market Cap<0.01
Net Debt to EBITDA―
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Neumora Therapeutics, Inc. has paid 178.00K in taxes.
Income Tax178.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Neumora Therapeutics, Inc. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Neumora Therapeutics, Inc. has $307.58M in cash and marketable securities with $1.85M in debt, giving a net cash position of -$305.73M billion.
Cash & Marketable Securities$307.58M
Total Debt$1.85M
Net Cash-$305.73M
Net Cash Per Share-$1.89
Tangible Book Value Per Share$1.80
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Neumora Therapeutics, Inc. is $5.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.67
Price Target Upside646.05% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast-0.42%